background


Product Information:

RLY2608

RLY-2608 is a first-in-class allosteric mutant-selective inhibitor of PI3Ka.

Cat. No.: EX-A8255    Purity: >98%
Chemical
Chemical structure of RLY2608


For research only, Do not use for Human!

SizeUnit Price (US$)StockQuantityOrder
50mg850In-stock
100mg1400In-stock
250mg2400In-stock
500mg3900In-stock
1gget quoteIn-stock
2gget quoteIn-stock


SynonymsRLY-2608
Synonyms 2RLY 2608
CAS No.2733573-94-7
Purity>98%
FormulaC29H14ClF5N6O2
Mol Weight608.905
Appearancesolid
SolubilitySoluble in DMSO
Shelf Life>2 years if stored properly
StoragePowder -20℃ 2 years; In solvent -20℃ 1 month;
ShippingShipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
 
 
Reference:  

[1]. Andreas Varkaris, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia. Cancer Discov. 2023 Nov 2.

CoACoA of RLY2608
Smiles:O=C1N[C@@H](C2=CC(F)=CC=C2Cl)C(C1=C3)=C(NC(C4=CC(F)=CC(C(F)(F)F)=C4)=O)C=C3C5=C(C#N)N6C(C=C5)=NC=N6

KEYWORDS: buy RLY2608 | RLY2608 supplier | purchase | cost | manufacturer | order | distributor | buy 2733573-94-7 | 2733573-94-7 supplier